Does Montelukast Cause Weight Gain? What the Science Says

Montelukast is not associated with weight gain in clinical trials, and it is not listed as a side effect on the drug’s prescribing label. Across studies in both adults and children, researchers have consistently found no meaningful change in body weight or body mass index attributable to the medication itself. Yet the question persists online, and for understandable reasons: some people do notice the number on the scale creeping up after starting the drug. The disconnect between the clinical data and individual experience has a few plausible explanations, most of which have less to do with montelukast’s pharmacology than with the broader context of living with asthma or allergies.

What the Trials Actually Measured

Montelukast (sold under the brand name Singulair and now widely available as a generic) has been studied in large, controlled trials since the late 1990s. When researchers have looked at body composition as an outcome, the results have been reassuringly flat. A retrospective analysis of four randomized trials comparing montelukast 10 mg daily to an inhaled corticosteroid-and-bronchodilator combination tracked patients across standard BMI categories, from underweight through severely obese, and found no signal that montelukast shifted patients into higher weight brackets.¹ The drug’s effect on asthma symptoms varied by weight category, but weight itself was not altered by the medication.

This absence of a weight signal is consistent with how montelukast works. It blocks a specific receptor involved in the inflammatory cascade triggered by leukotrienes, chemical messengers released during allergic and asthmatic responses. Unlike systemic corticosteroids, which can directly increase appetite and promote fat storage, montelukast’s mechanism of action is narrow. It does not interact with the hormonal pathways most commonly implicated in drug-induced weight gain, such as insulin signaling, cortisol regulation, or serotonin-mediated appetite control.

Pediatric Evidence on Growth and BMI

Parents are often the ones asking this question, since montelukast is frequently prescribed to young children with asthma or allergic rhinitis. The pediatric data is particularly clear. A 56-week randomized, double-blind study comparing montelukast, beclomethasone (an inhaled corticosteroid), and placebo in prepubertal children found that growth rates in the montelukast group were virtually identical to those in the placebo group, with a mean difference of just 0.03 cm over the course of a year.² Children on montelukast grew at the same pace as children taking a sugar pill.

A separate study tracking height, weight, and BMI standard deviation scores in children on either inhaled corticosteroids or montelukast found no difference between the two groups at any point during the study period. The researchers concluded that commonly prescribed doses of both medications are safe and do not affect BMI or growth in asthmatic children.³ When montelukast has been used in other pediatric contexts, such as treating mild obstructive sleep apnea in children, trials have similarly reported no side effects related to weight.⁴

For parents worried about their child’s growth trajectory while on montelukast, the evidence is about as clean as it gets in pharmacology research. The drug does not appear to affect weight, height, or body composition in children at standard doses.

A Curious Wrinkle in Cell Biology

Interestingly, laboratory research on fat cells suggests that drugs in montelukast’s class might, if anything, work against fat accumulation rather than promote it. Leukotrienes, the inflammatory molecules that montelukast blocks, turn out to play a role in how fat cells develop. A study on adipocyte cell lines found that leukotrienes C4 and D4 increased triglyceride levels and activated genes involved in fat cell formation. When researchers blocked the CysLT1 receptor (the same receptor montelukast targets in the lungs) with a related drug called pranlukast, that fat-promoting effect was suppressed.⁵

The researchers went so far as to suggest that leukotriene receptors could be novel targets for treating obesity. This is a far cry from montelukast causing weight gain. If the cell-culture findings translated directly to humans, you might even expect a modest anti-obesity effect. But cell studies and whole-body metabolism are different things, and nobody should take montelukast hoping to lose weight. The point is simply that the drug’s basic biology pushes against the idea that it would make you fatter.

Why People Still Suspect the Drug

If the evidence is this consistent, why do some people feel certain they gained weight after starting montelukast? A few factors likely explain the disconnect.

The most straightforward one is timing. Montelukast is often prescribed alongside other asthma medications, and the condition itself tends to worsen during periods when physical activity drops. Asthma that is poorly controlled naturally limits exercise capacity. Research on physical activity in asthma patients has found that better short-term asthma control and lower BMI are both independently associated with higher levels of physical activity.⁶ The relationship runs in both directions: people whose asthma worsens tend to move less, and people who move less tend to gain weight. If montelukast is added during a period of worsening symptoms, any concurrent weight gain may be blamed on the new pill rather than the underlying decline in activity.

Another confounder is oral corticosteroid use. Patients with moderate to severe asthma often receive short courses of prednisone or prednisolone during flare-ups. These systemic steroids are well known to increase appetite and promote fluid retention. A person who starts montelukast around the same time they receive a steroid burst may attribute the resulting puffiness or hunger to the wrong medication. That said, even short-term oral corticosteroid courses in stable asthma have been studied, and one randomized controlled trial found no significant changes in dietary intake, body weight, or body fat percentage during a brief course.⁷ The weight effects of steroids tend to accumulate with repeated or prolonged use, not from a single course.

Sleep Problems and the Indirect Path to Weight Change

One area where montelukast may indirectly influence weight, though the connection remains speculative, is through its effects on sleep. The drug carries a boxed warning from the FDA about neuropsychiatric events, and a systematic review of the evidence found that montelukast was associated with a higher risk of sleep problems, including insomnia.⁸ Poor sleep is one of the more reliable predictors of weight gain in the general population. It disrupts hunger hormones, increases cravings for calorie-dense foods, and saps the motivation to exercise.

If montelukast is causing or worsening insomnia in a given person, the downstream metabolic effects of chronic poor sleep could plausibly lead to gradual weight gain over months. This would not show up in a typical clinical trial designed to measure lung function over 12 weeks, because the weight change would be slow, small, and mediated by behavior rather than pharmacology. It is the kind of effect that only becomes visible in someone’s life over a longer time horizon.

Mood changes, another recognized neuropsychiatric effect of montelukast, could also play a role for some individuals. Depression and anxiety alter eating patterns in unpredictable ways, and both are reported at low rates in people taking the drug. For someone who experiences mood disturbance as a side effect, changes in appetite or comfort eating could follow. Again, this is not montelukast acting on fat cells or metabolism. It is the drug affecting the brain, and the brain affecting behavior.

Individual Variation in Drug Response

Not everyone responds to montelukast the same way, and genetics are part of the reason. A study examining leukotriene pathway gene variants found that genetic variation in candidate genes contributes to variability in how well patients respond to the drug.⁹ While this research focused on asthma outcomes rather than weight, it underscores a broader principle: the same drug can behave differently in different people depending on their genetic makeup.

It is plausible that certain genetic profiles might predispose a small number of people to metabolic side effects that do not appear in aggregate trial data. Clinical trials report averages. If two percent of participants gain five pounds and the other 98 percent do not, the average weight change is essentially zero, and the trial reports no effect. That does not mean nothing happened to those two percent. Rare or low-frequency side effects are notoriously difficult to detect in trials sized for lung function endpoints. Pharmacovigilance databases, which collect voluntary reports of adverse events after a drug is on the market, can sometimes pick up signals that trials miss, but these reports cannot prove causation. A report that someone gained weight while taking montelukast does not establish that montelukast caused the weight gain, only that the two events coincided.

Sorting Out What to Do

If you have noticed weight gain since starting montelukast, the practical question is whether the drug is responsible and whether switching medications would help. Based on current evidence, montelukast is unlikely to be the direct cause. But that does not mean your experience is imaginary. A few questions are worth working through with your prescriber:

Sleep quality: Has your sleep worsened since starting the medication? If so, disrupted sleep could be driving changes in appetite and energy expenditure. Addressing the sleep issue, whether by switching drugs, adjusting timing, or adding sleep hygiene measures, may resolve the weight problem indirectly.
Mood changes: Have you noticed new anxiety, irritability, or low mood? Neuropsychiatric effects of montelukast can be subtle, and mood shifts often alter eating behavior before the person recognizes the mood change itself.
Steroid exposure: Have you also been taking oral corticosteroids, even in short bursts? Repeated courses add up, and the metabolic effects of steroids can persist for weeks after each course ends.
Activity level: Has your asthma limited your ability to exercise, or has a change in season or routine reduced your movement? Asthma and inactivity are tightly linked, and the effect on weight can be significant over months.

If none of these explanations fit, and you are confident the weight change started with montelukast and nothing else changed, it is reasonable to ask your doctor about a trial off the medication. Alternatives for mild persistent asthma include low-dose inhaled corticosteroids, which have strong safety data and, as the pediatric studies noted, do not affect BMI at commonly prescribed doses.³ For allergic rhinitis, intranasal steroids or antihistamines are standard alternatives that carry no weight-related concerns.

When Better Breathing Leads to Better Eating

There is one more scenario that rarely gets discussed: some people may actually eat more after starting montelukast because they feel better. When your airways open up, when nighttime coughing stops, when you can breathe through your nose for the first time in months, your appetite can return with surprising force. Chronic nasal congestion blunts the sense of smell and taste, and both of those senses drive appetite. Restoring them can make food more appealing. This is not a side effect in any pharmacological sense. It is a consequence of the drug working as intended. But if someone has been eating less because of chronic congestion and then regains a normal appetite, a few pounds of weight gain over subsequent months is predictable.

This phenomenon is better documented in the context of other treatments that restore airflow, such as adenotonsillectomy in children with sleep-disordered breathing, where catch-up weight gain is expected and considered healthy. For adults with allergic rhinitis who start montelukast and suddenly find dinner more enjoyable, the mechanism is probably similar, even if the scale of the effect is smaller. It can feel like the drug “caused” weight gain when what actually happened is that effective treatment restored a normal relationship with food.